Partner Fund Management L.P. lowered its holdings in shares of Arcus Biosciences Inc (NYSE:RCUS) by 17.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 768,279 shares of the company’s stock after selling 165,007 shares during the quarter. Partner Fund Management L.P. owned about 1.73% of Arcus Biosciences worth $9,404,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Foresite Capital Management III LLC bought a new position in Arcus Biosciences in the 1st quarter worth $42,080,000. Hillhouse Capital Management Ltd. raised its holdings in Arcus Biosciences by 80.5% in the 2nd quarter. Hillhouse Capital Management Ltd. now owns 767,128 shares of the company’s stock worth $9,390,000 after acquiring an additional 342,128 shares during the period. Foresite Capital Management IV LLC bought a new position in Arcus Biosciences in the 1st quarter worth $10,036,000. Board of Trustees of The Leland Stanford Junior University bought a new position in Arcus Biosciences in the 1st quarter worth $9,651,000. Finally, BlackRock Inc. raised its holdings in Arcus Biosciences by 1,606.3% in the 2nd quarter. BlackRock Inc. now owns 335,270 shares of the company’s stock worth $4,104,000 after acquiring an additional 315,621 shares during the period. Institutional investors and hedge funds own 39.02% of the company’s stock.

NYSE RCUS opened at $14.19 on Friday. Arcus Biosciences Inc has a 52-week low of $10.80 and a 52-week high of $22.10.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Monday, August 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.08. The company had revenue of $1.25 million during the quarter, compared to analyst estimates of $1.30 million. equities analysts expect that Arcus Biosciences Inc will post -1.81 EPS for the current year.

Separately, Zacks Investment Research upgraded shares of Arcus Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, July 11th.

In related news, President Juan C. Jaen purchased 10,000 shares of the firm’s stock in a transaction on Monday, August 13th. The shares were bought at an average cost of $11.88 per share, for a total transaction of $118,800.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Terry J. Rosen purchased 9,929 shares of the firm’s stock in a transaction on Monday, August 13th. The stock was bought at an average price of $11.87 per share, for a total transaction of $117,857.23. The disclosure for this purchase can be found here. Insiders acquired a total of 85,117 shares of company stock worth $1,118,707 over the last 90 days.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody.

Read More: Dow Jones Industrial Average (DJIA)

Institutional Ownership by Quarter for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.